

Supplementary Table S 1. Clinical validation of potential metastasis suppressors described in the literature (Horack et al. 2008). In bold, those whose expression in the primary tumor predicts risk of site-specific relapse.

Gene symbol	Hazard Ratio of overall Mets	Hazard Ratio of Lung* Mets	Hazard Ratio of Brain* Mets	Hazard Ratio of Bone Mets
PEBP1	-1,10	-1,44**	-1,43	-1,01
RARRES3	-1,03	-1,31	-1,01	1,02
SMAD7	-1,08	-1,20	-1,37	-1,05
ARHGDIB	-1,02	-1,16	1,21	1,04
BRMS1	-1,06	-1,15	-1,12	-1,03
CASP8	1,02	-1,15	1,02	1,01
CDH1	-1,06	-1,12	1,07	-1,03
MAP2K7	-1,06	-1,12	-1,24	-1,04
AKAP12	1,01	-1,09	1,11	1,04
CLDN4	-1,03	-1,09	1,07	1,04
SOCS3	-1,03	-1,06	-1,16	1,05
GPR68	1,01	-1,03	-1,19	1,06
MAP2K6	1,01	-1,02	-1,21	1,04
MAP2K4	-1,03	-1,01	1,18	-1,04
MATN2	-1,01	1,01	1,29	-1,11
MED23	1,04	1,02	-1,11	1,08
GSN	-1,03	1,06	1,16	-1,00
RECK	1,05	1,07	-1,06	1,01
CTGF	1,04	1,11	1,03	1,05
CD44	1,01	1,11	1,13	-1,01
DCC	1,06	1,13	1,25	1,07
NME1	-1,00	1,16	1,24*	-1,13
KISS1	1,08	1,18	1,67	1,06
DLC1	1,07	1,21*	-1,04	1,11
DRG1	1,04	1,33*	1,01	-1,10
CD82	1,04	1,39	1,26	-1,03

*p<0.01
**p=0.019